{"paper_id":"0bed07af-e84b-4f87-9aa8-6a51818e5a70","body_text":"The authors are grateful to Ms. Linda Fineder, Ms. Andrea Sapinsky, and Ms. Ruth Lenners for excellent technical assistance and to Stephan Kropshofer, M.D., and Sigfried Fessler, M.D., for help in specimen collection.\n\nK.T.B. is a consultant for Pfizer and Swiss Precision Diagnostics and a clinical trial investigator for Boehringer Ingelheim, Third Wave, Wyeth-Ayerst, and Xanodyne. H.D. is owner of Vitater Biotechnology. B.E.S. has nothing to disclose. T.C. has nothing to disclose. H.B. has nothing to disclose. C.S. has nothing to disclose. G.D. has nothing to disclose. L.W. has nothing to disclose.\nSupported by grants from the Jubiläumsfonds of the Austrian National Bank to B.E.S. (Project 12724) and H.D. (12529) and from the Austrian Science Fund to H.D. (P19969-B11).","source_license":"CC0","license_restricted":false}